How does neuroblastoma begin and can we use this knowledge to develop new treatments?
Dissecting the role of MYCN in neuroblastoma initiation
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Dissecting the role of MYCN in neuroblastoma initiation
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes
Deciphering the genomic landscape of childhood refractory t-cell acute lymphoblastic leukaemia
Investigating repurposed drugs to decrease the progression of Ewing’s sarcoma
What helps and what hinders in remotely delivered acceptance and commitment therapy for survivors of childhood brain tumours: a diary and interview study.
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?